■尽管替莫唑胺已被广泛用于治疗各种肿瘤,缺乏关于替莫唑胺毒性特征的大队列研究。分析了使用替莫唑胺治疗的患者的毒性特征和相关因素。
■2008年1月至2019年12月华中科技大学附属协和医院接受替莫唑胺治疗的患者。回顾性分析含替莫唑胺方案治疗患者的临床资料。采用单因素卡方检验和多因素logistic回归分析确定与毒性发生相关的因素。
■在1057名接受替莫唑胺治疗的患者中,我们的分析包括922例患者。在922名患者中,484例患者(52.5%)出现毒性反应。单因素分析显示放疗,化疗周期,化疗方案,临床分期与替莫唑胺治疗期间的毒副反应显著相关(P<0.05)。化疗方案,化疗周期,临床分期与总的毒副反应发生显著相关(P<0.05)。化疗方案,化疗周期,临床分期与血液系统的毒性有关,而性别,年龄,临床诊断,临床分期与胃肠道毒性有关(P<0.05)。临床诊断,化疗方案,年龄与肝毒性相关(P<0.05)。
■在接受含有替莫唑胺的方案的患者中,毒性是常见的。临床医生应该意识到与毒性相关的因素,以尽量减少毒性的影响。
OBJECTIVE: Although temozolomide has been extensively used to treat various tumors, there is a lack of large-cohort studies on temozolomide\'s toxicity profile. The toxicity profiles and associated factors in patients treated with temozolomide-containing regimens were analyzed.
METHODS: Patients treated with temozolomide-containing regimens in the Affiliated Union Hospital of Huazhong University of Science and Technology from January 2008 to December 2019 were included. A retrospective analysis of the clinical data of patients treated with temozolomide-containing regimens was performed. Univariate chi-square test and multivariate logistic regression analysis were employed to identify factors associated with the occurrence of toxicities.
RESULTS: Among the 1057 patients received temozolomide-containing regimens, 922 patients were included in our analyses. Of the 922 patients, 484 patients (52.5%) experienced toxicities. Univariate analysis revealed that radiotherapy, chemotherapy cycle, chemotherapy regimen, and clinical stage were significantly associated with the toxicity during temozolomide treatment (P < 0.05). The chemotherapy regimen, chemotherapy cycle, and clinical stage were significantly associated with the overall occurrence of toxicities (P < 0.05). A chemotherapy regimen, chemotherapy cycle, and clinical stage were associated with the hematological system\'s toxicities, whereas gender, age, clinical diagnosis, and clinical stage were related to gastrointestinal toxicities (P < 0.05). Clinical diagnosis, chemotherapy regimen, and age were associated with liver toxicity (P < 0.05).
CONCLUSIONS: Toxicities are common among patients receiving temozolomide-containing regimens. Clinicians should be aware of factors associated with toxicities to minimize the impact of the toxicity.